Despite positive clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from pharmacy benefit managers. The companies are https://berthatmjq754487.arwebo.com/64598543/the-vyndamax-faces-is-meeting-pbm-hurdles-a-copyrightination-at-reimbursement-fights